ResMed (NYSE:RMD) had a weak trading session and its shares were last down at $59.69, down -0.11% or -0.18 points. The trading data also revealed that the total net flow stood at $1.76 million as the shares had $4.37 million in upticks but lost $2.61 million in downticks. The up/down ratio was 1.67. This data is particularly important for the traders and speculators alike as it could also be used to gauge the strength of the momentum in the shares. During the past week, the shares have seen a change of 0.25% in the shares.The block trade data suggests an inflow of $1.46 million in upticks and an outflow of $0 million in downticks. The up/down ratio for the block stood at 0. The net money flow for this transaction was recorded at $1.46.
Currently the company Insiders own 2.54% of ResMed shares according to the proxy statements. Institutional Investors own 58.75% of ResMed shares. During last six month period, the net percent change held by insiders has seen a change of -13.03%. On the companys insider trading activities, The director, of Resmed Inc, Farrell Peter C had unloaded 20,000 shares at $59.82 per share in a transaction on June 6, 2016. The total value of transaction was $1,196,400. The Insider information was revealed by the Securities and Exchange Commission in a Form 4 filing.
ResMed (NYSE:RMD) stock ended Monday session in the red zone in a volatile trading. The stock closed down 0.58 points or 0.97% at $59.22 with 759,812 shares getting traded. Post opening the session at $59.46, the shares hit an intraday low of $59.2 and an intraday high of $59.87 and the price was in this range throughout the day. The company has a market cap of $8,315 million and the number of outstanding shares have been calculated to be 140,409,810 shares. The 52-week high of ResMed (NYSE:RMD) is $61.23 and the 52-week low is $48.99.
Many analysts have stated their opinion on the company shares. Macquarie upgrades its rating on ResMed (NYSE:RMD). Analysts at the Macquarie have a current rating of Neutral on the shares. The shares were previously rated Underperform. The rating by the firm was issued on April 28, 2016.
ResMed Inc. is engaged in the development, manufacturing, distribution and marketing of medical products for the diagnosis, treatment and management of respiratory disorders, with a focus on sleep-disordered breathing (SDB). The Company develops various products for SDB and other respiratory disorders, including airflow generators, diagnostic products, mask systems, headgear and other accessories. It produces continuous positive airway pressure, variable positive airway pressure and AutoSet systems for the titration and treatment of SDB. Its products also include S9 Escape, AirSense 10 Elite, AirSense 10 CPAP, S9 VPAP S, S9 VPAP ST, S9 VPAP Adapt, S9 VPAP ST-A, S9 VPAP COPD and AirCurve 10 V Auto, among others. It markets sleep recorders for the diagnosis and titration of SDB in sleep clinics and hospitals. Its products include Quattro FX, Swift FX for Her, Mirage FX for Her, Pixi Pediatric Mask, Quattro FX for Her, Swift FX Bella, Swift FX Nano, AirFit N10 and Apnealink Air.